Live Events

CME Requirements By State

Live Events

July
8
Thursday
7:00 PM EDT

GLP-1 RAs

The Contemporary Use of GLP-1 RAs to Individualize Therapy in T2DM: Candid Conversations on Glycemic and Nonglycemic Effects

James R. Gavin III, MD, PhD
Healing Our Village, Inc.
Emory University School of Medicine
Atlanta, Georgia

July
22
Thursday
7:00 PM EDT

Gastric and GEJ Cancer

Redrawing the Algorithm in Gastric and GEJ Cancers: Treatment Planning and Sequencing in the Era of Immunotherapy

Manish A. Shah, MD, FASCO
Sandra and Edward Meyer Cancer Center at Weill Cornell Medicine
Weill Cornell Medicine/New York-Presbyterian Hospital
New York, New York

August
3
Tuesday
7:00 PM EDT

Venous Thromboembolism (VTE)

Reducing the Global Burden of Cancer-Associated VTE: Applying Guideline-Concordant, Evidence-Based Care & Shared Decision-Making Strategies to Improve Patient Outcomes

Alok A. Khorana, MD, FACP, FASCO
Taussig Cancer Institute
Cleveland Clinic Lerner School of Medicine
Case Western Reserve University
Cleveland, Ohio

Robert D. McBane, II, MD
Mayo Clinic Gonda Vascular Center
Rochester, Minnesota

August
19
Thursday
7:00 PM EDT

B-Cell Cancers

The Next Building Block for B-Cell Cancer Care: Exploring Personalized Treatment With Emerging BTK Inhibitor Options in CLL/SLL and MCL

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

August
26
Thursday
7:00 PM EDT

Psoriasis

Taking Aim at the TYK2 Pathway in Psoriasis: Addressing Unmet Treatment and Patient Needs With an Innovative Therapeutic Approach

April W. Armstrong, MD, MPH
Southern California Clinical and Translational Science Institute (SC CTSI)
Keck School of Medicine
University of Southern California
Los Angeles, California

Kenneth B. Gordon, MD
Medical College of Wisconsin
Milwaukee, Wisconsin

September
1
Wednesday
7:00 PM EDT
September
9
Thursday
6:15 AM CDT

Chronic Lymphocytic Leukemia

Seizing the Day With BTK Inhibitors in CLL: Evidence-Informed Therapy Selection, Safety, and Sequential Care

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Jennifer Woyach, MD
The Ohio State University
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
Columbus, Ohio

September
10
Friday
6:30 AM CDT

Myelofibrosis

Understanding the Clinical Spectrum of Myelofibrosis: Expert Perspectives on Molecular Biology, JAK Inhibitors, and Emerging Therapeutics

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Ruben A. Mesa, MD, FACP
Mays Cancer Center at UT Health San Antonio MD Anderson
San Antonio, Texas

September
14
Tuesday
5:00 PM EDT

Non–Small Cell Lung Cancer

Harnessing the Potential of HER2-, HER3-, and TROP2-Targeted Therapies to Address Unmet Needs in Advanced NSCLC

Melissa L. Johnson, MD
Sarah Cannon Research Institute
Nashville, Tennessee

September
14
Tuesday
7:00 PM EDT

Multiple Myeloma

Breaking Therapeutic Barriers in RRMM: Team-Based Solutions for Integrating Novel Antibody Platforms and Improving Myeloma Care

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

September
28
Tuesday
5:00 PM CDT

Immuno-Oncology Biomarkers

Evolving Standards in Biomarker Testing, Scoring, and Results Interpretation Driven by the Broadening Role of Cancer Immunotherapy

Kurt A. Schalper, MD, PhD
Assistant Professor of Pathology and Medical Oncology
Yale School of Medicine
Director, Translational Immuno-Oncology Laboratory
Yale Cancer Center
New Haven, Connecticut

October
22
Friday
6:00 PM PDT

Eosinophilic Esophagitis

Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina

October
24
Sunday
6:30 PM CDT

Pan Tumor

Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

October
25
Monday
7:00 AM EDT

Immune-Related Adverse Events

Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts

Christopher Baugh, MD, MBA
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

October
26
Tuesday
7:00 AM EDT

Multiple Sclerosis

Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
27
Wednesday
7:00 PM EDT

Multiple Sclerosis

Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

October
29
Friday
12:30 PM EDT
October
29
Friday
6:05 PM EDT

Small Cell Lung Cancer

Translating Science, Transforming Practice, and Making Headway Toward Better Outcomes in SCLC: Immunotherapy Has Changed the Game, but Where Do We Go Next?

Jonathan W. Goldman, MD
UCLA Jonsson Comprehensive Cancer Center
Ronald Reagan UCLA Medical Center
UCLA Health - Santa Monica Medical Center
Santa Monica, California

November
2
Tuesday
7:00 PM EDT
November
8
Monday
7:00 PM EST
November
3
Wednesday
12:30 PM EDT

Atopic Dermatitis

Expert Insights From Around the Globe on Tailoring Treatment for Patients With Atopic Dermatitis

Emma Guttman-Yassky, MD, PhD
Icahn School of Medicine
Mount Sinai Medical Center
New York, New York

November
3
Wednesday
7:00 PM EDT
November
15
Monday
7:00 PM EST

Esophageal/GEJ Cancer

Immunotherapy at the Cutting Edge in Resectable Esophageal/GEJ Cancer: Preparing Thoracic Surgeons and the Broader Multidisciplinary Team to Navigate Changing Standards of Care

Ronan J. Kelly, MD, MBA
Director of the Charles A. Sammons Cancer Center at Baylor University Medical Center, Dallas, Texas
Chief of Oncology, Baylor Scott & White Health System (NTx)
W.W. Caruth Jr. Chair of Immunology at Baylor University Medical Center
Clinical Professor, Texas A&M University College of Medicine
Adjunct Associate Professor of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland
Professor, Clinical Sciences Division at the Translational Genomics Research Institute
Phoenix, Arizona

Daniela Molena, MD
Director, Esophageal Surgery Program
Memorial Sloan Kettering Cancer Center
New York, New York

November
4
Thursday
9:00 PM EDT

Renal Cell Carcinoma

Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
4
Thursday
7:00 PM EDT
November
22
Monday
7:00 PM EST

NSCLC

Has Immunotherapy Brought Us to an Inflection Point in the Multimodal Management of Stage I-III NSCLC? Dissecting the Data and Instituting Multidisciplinary Alliances to Improve Outcomes in Early-Stage Disease

Stephen R. Broderick, MD, MPHS
Johns Hopkins University School of Medicine
Johns Hopkins Kimmel Cancer Center
Baltimore, Maryland

Heather A. Wakelee, MD
Stanford Cancer Center
Stanford, California

November
7
Sunday
5:30 PM EST

Interstitial Lung Disease

Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

November
8
Monday
7:00 PM EST
November
15
Monday
7:00 PM EST

Breast Cancer

Raising the Bar in HR+/HER2- Early Breast Cancer: Multidisciplinary Strategies for Integrating the CDK4 and 6 Inhibitors

Joyce O’Shaughnessy, MD
Baylor University Medical Center
Dallas, Texas

November
9
Tuesday
7:00 PM EST

Obesity

Gut Feeling: The Increasing Importance of GLP-1–Based Therapies for Personalized Obesity Management

Domenica M. Rubino, MD
Washington Center for Weight Management and Research
Arlington, Virginia

Donna H. Ryan, MD, FTOS
Pennington Biomedical Research Center
Baton Rouge, Louisiana

November
10
Wednesday
7:00 PM EST

Interstitial Lung Disease

Covering All the Bases in SSc-ILD Care: Expert Strategies for Diagnosis, Treatment, and Managing Comorbidities

Lorinda Chung, MD, MS
Stanford University School of Medicine
Palo Alto, California

November
13
Saturday
6:30 AM EST

Hypertrophic Cardiomyopathy

Making New Strides in Hypertrophic Cardiomyopathy: The Latest Guidelines, Science, and Strategies for Early Diagnosis and Tailored Treatment

Neal K. Lakdawala, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

Anjali Tiku Owens, MD
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

November
14
Sunday
8:30 AM EST
November
17
Wednesday
7:00 PM EST

HCC/Liver Cancer

Harmonizing HCC Care With a Multidisciplinary Ensemble: Guidance for the Era of Novel Locoregional, Multimodal, and Systemic Strategies

Amit Singal, MD, MS
Professor of Medicine
Willis C. Maddrey Chair in Liver Disease
Chief of Hepatology and Medical Director of the Liver Tumor Program
UT Southwestern Medical Center
Dallas, Texas

November
14
Sunday
5:00 PM EST

Cardiac irAEs

Improving the Detection and Management of Cardiac Immune-Related Adverse Events in Patients With Cancer Is a Must: Are You Prepared?

Javid Moslehi, MD
UCSF School of Medicine
Cardiovascular Research Institute (CVRI)
San Francisco, California

November
16
Tuesday
7:00 PM EST

HIV

Parallel Perspectives: A Unique Look at HIV Treatment Decisions From the Provider and the Patient

David Malebranche, MD, MPH
Internal Medicine Physician
Atlanta, Georgia

Peter Shalit, MD, PhD
University of Washington
Seattle, Washington

November
20
Saturday
12:45 PM EST

Glioblastoma

A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Tuesday
5:45 PM EST

Bladder Cancer

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

December
1
Wednesday
7:00 AM EST

Prostate Cancer

Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana

December
7
Thursday
8:00 AM EST

Hyperkalemia

Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

December
10
Friday
7:00 AM EST

Follicular Lymphoma

A Better Blend for Follicular Lymphoma: How Targeted, Epigenetic, and Immune Therapies Are Changing Patient Care

Nathan H. Fowler, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:30 AM EST

Chronic Lymphocytic Leukemia (CLL)

Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
10
Friday
7:30 AM EST

Multiple Myeloma

A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

December
10
Friday
7:30 AM EST

Diffuse Large B-Cell Lymphoma

Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
10
Friday
7:30 AM EST

Acute Myeloid Leukemia

Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:30 AM EST
December
17
Friday
6:30 PM EST

Sickle Cell Disease

The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut

December
14
Tuesday
10:00 AM EST

Eosinophilic Esophagitis

Expert Perspectives on Improving Early Recognition of Eosinophilic Esophagitis and Examining the Potential Clinical Utility of Emerging Targeted Therapy

Chris A. Liacouras, MD
The Children's Hospital of Philadelphia
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

December
21
Tuesday
7:00 PM EST

Hyperkalemia

Advancing the Standard of Care for Patients With Hyperkalemia: Insights and Evidence for Clinical Pharmacy Practice

George L. Bakris, MD
American Heart Association Comprehensive Hypertension Center
University of Chicago Medicine
Chicago, Illinois

Joanna Hudson, PharmD, BCPS, FASN, FCCP, FNKF
The University of Tennessee Health Science Center
Memphis, Tennessee

January
20
Thursday
6:30 PM PST

Hepatocellular Carcinoma

Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
21
Friday
6:15 PM PST
January
29
Saturday
1:30 PM EST

NSCLC

Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

January
30
Sunday
1:00 PM EST

NSCLC

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

February
9
Wednesday
7:00 PM CST

Stroke

Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California

S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas

February
17
Thursday
7:00 PM PST
February
17
Thursday
7:00 PM PST

Bladder Cancer

Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

February
18
Friday
6:30 PM PST

Prostate Cancer

Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
22
Tuesday
3:05 PM PST
March
8
Tuesday
6:30 PM EST

NSCLC

Addressing Key Targets in Advanced NSCLC: Evaluating the Latest Evidence and Clinical Opportunities for HER2-, HER3-, and TROP2-Targeted Therapies

Pasi A. Jänne, MD, PhD
Lowe Center for Thoracic Oncology
Belfer Institute for Applied Cancer Science, Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

February
23
Wednesday
7:00 PM EST

NSCLC

Can the Addition of Immunotherapy to Multimodal Management of Stage I-III NSCLC Help Break the Stalled Cycle of Poor Outcomes?

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

February
24
Thursday
7:00 PM EST

NSCLC

Bringing Precision Oncology to Early-Stage Lung Cancer, With Adjuvant EGFR-Targeted Therapy Leading the Way: What Thoracic Surgeons Need to Know and Do

Boris Sepesi, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Tina Cascone, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
25
Friday
7:00 PM EST
March
7
Monday
7:00 PM EST

Multiple Sclerosis

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland

*Participation in this CME event as an "outside activity"

February
28
Monday
7:00 AM MST

Severe Asthma

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California

March
10
Thursday
7:15 PM CST

Melanoma

Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
11
Friday
5:15 PM CST

Breast Cancer

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas

March
21
Monday
3:00 PM MST

Ovarian Cancer

When Are PARP Inhibitors the Best Choice for Patients With Ovarian Cancer? Personalizing Therapeutic Selection Across the Disease Continuum

Bradley J. Monk, MD, FACS, FACOG
University of Arizona College of Medicine
Creighton University School of Medicine
GOG-Foundation
Phoenix, Arizona

March
22
Tuesday
6:15 AM PDT

Immuno-Oncology Biomarkers

Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
23
Wednesday
6:15 AM PDT

HER2/HER3/TROP2 Testing/Treatment

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
31
Thursday
7:00 PM EDT

Cancer Screening

Cancer Screening and Preventive Care for Transgender Individuals: Patient and Provider Perspectives on Best Practices and Special Considerations

Elizabeth Eaman, MD
Oodle Family Medicine
Renton, Washington
Healthy Transitions, LLC
Montclair, New Jersey
University of Washington
Seattle, Washington

April
7
Thursday
7:00 PM EDT

T2DM and Obesity

Is Synergism the Secret to Success? Candid Conversations on Targeting GIP and GLP-1 to Individualize Treatment in Patients With T2DM and Obesity

Javier Morales, MD, FACP, FACE
Donald and Barbara Zucker School of Medicine
Hofstra Northwell Hempstead
Advanced Internal Medicine Group, PC
East Hills, New York

April
9
Saturday
7:00 PM CDT

Cancer Immunotherapy

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland

April
12
Tuesday
6:00 PM CDT

Ovarian Cancer

Making Sense of The Evolving Treatment Landscape in Ovarian Cancer Care: Pharmacy Perspectives on PARP Inhibitor Therapy

Thomasina Morris, RPh, MHA, BCOP
Moffitt Cancer Center
Tampa, Florida

April
19
Tuesday
7:00 PM EDT
April
26
Tuesday
7:00 PM EDT
April
28
Thursday
12:15 PM PDT
April
29
Friday
6:00 AM PDT

Chronic Lymphocytic Leukemia

Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
30
Saturday
6:00 PM PDT
May
5
Thursday
7:30 AM EDT

Neurofibromatosis

Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC

May
5
Thursday
12:45 PM EDT

Acute Lymphoblastic Leukemia

Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota

Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia

May
14
Saturday
12:30 PM EDT

NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

May
14
Saturday
6:00 PM CDT
June
1
Wednesday
7:30 PM EDT

Asthma

The Future of Severe Asthma Treatment Is Here: Expert Insights on the Rationale for Targeting Epithelial Alarmins

Reynold A. Panettieri, Jr., MD
Robert Wood Johnson Medical School
Rutgers Institute for Translational Medicine and Science
Rutgers University
New Brunswick, New Jersey
University of Pennsylvania

Eileen Wang, MD, MPH
National Jewish Health
University of Colorado School of Medicine
Denver, Colorado

June
2
Thursday
7:00 AM EDT

Multiple Sclerosis

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
3
Friday
7:00 PM CDT

Chronic Lymphocytic Leukemia

Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
3
Friday
7:00 AM EDT

Multiple Sclerosis

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

June
3
Friday
7:00 PM CDT
June
3
Friday
7:00 PM CDT

AML

The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
3
Friday
7:00 PM CDT

Small Cell Lung Cancer

Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Friday
7:00 PM CDT

RCC

Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
6:00 AM CDT

DR/DME

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
12:30 PM EDT

COVID-19

Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

June
4
Saturday
7:00 PM CDT

CAR-T THERAPY

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice

Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
4
Saturday
7:00 PM CDT

HCC/LIVER CANCER

Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

June
4
Saturday
7:00 PM CDT

NSCLC

Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

June
4
Saturday
7:00 PM CDT

MULTIPLE MYELOMA

The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
4
Saturday
7:00 PM CDT

HEAD AND NECK CANCER

The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
5
Sunday
7:00 PM CDT

NSCLC

Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio

June
5
Sunday
7:00 PM CDT

MELANOMA

Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia

June
5
Sunday
7:00 PM CDT

BASAL CELL CARCINOMA

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
5
Sunday
7:00 PM CDT
June
5
Sunday
7:00 PM CDT
June
15
Wednesday
12:00 PM EDT
June
15
Wednesday
7:00 PM EDT
July
1
Friday
13:40 CEST

Gastric Cancer

Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York

July
12
Tuesday
7:00 PM EDT

Diabetic Macular Edema and Diabetic Retinopathy

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

July
12
Tuesday
7:00 PM EDT

Basal Cell Carcinoma

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

July
13
Wednesday
7:00 PM EDT

Nontuberculous Mycobacterial Lung Disease

Confronting the Challenges of Nontuberculous Mycobacterial Lung Disease: Expert Strategies for Reducing Diagnostic Delays and Improving Adherence to Guideline-Based Treatment

Julie V. Philley, MD
University of Texas at Tyler Health Science Center
Tyler, Texas

Kevin Winthrop, MD, MPH
Oregon Health & Science University
Portland, Oregon

July
28
Thursday
12:00 PM EDT
September
1
Thursday
6:00 PM CDT

MANTLE CELL LYMPHOMA

Rebooting the BTK Inhibitor Sequence in MCL: Team-Centered Guidance on the Personalized Selection of Covalent and Noncovalent BTK Inhibitors in Relapsed/Refractory Disease

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Nirav Shah, MD, MS
Froedtert Hospital and the Medical College of Wisconsin
Milwaukee, Wisconsin

September
24
Saturday
6:45 AM CDT

Small Cell Lung Cancer

Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

September
25
Sunday
6:45 AM CDT

NSCLC

Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada

September
26
Monday
6:00 PM CDT

MYELODYSPLASTIC SYNDROMES

The “Innovation Moment” Arrives for MDS: Guidance on Building Personalized Management Plans to Improve Patient Outcomes

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

September
27
Tuesday
12:00 PM EDT

ATOPIC DERMATITIS

Using Biologics to Manage Moderate to Severe Atopic Dermatitis: Compare Your Approach With Experts From Around the World

Professor Jacob P. Thyssen
Bispebjerg Hospital
University of Copenhagen
Copenhagen, Denmark

September
28
Wednesday
12:41 PM CDT

ACUTE MYELOID LEUKEMIA

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

September
28
Wednesday
12:41 PM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Deborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

September
29
Thursday
11:50 AM CDT

MULTIPLE MYELOMA

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
29
Thursday
7:00 PM EDT

DIABETIC MACULAR EDEMA AND DIABETIC RETINOPATHY

A Call to Action for Primary Care Professionals: Your Role in Saving the Eyesight of Patients With Diabetes

Mark W. Stolar, MD
Feinberg School of Medicine
Northwestern University
Chicago, Illinois

September
30
Friday
12:30 PM EDT

NSCLC

Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings

Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

September
30
Friday
6:45 PM EDT

NSCLC

Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

September
30
Friday
7:00 PM CDT

MULTIPLE MYELOMA

The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity

Praneetha Thulasi, MD
Emory Eye Center
Emory University School of Medicine
Atlanta, Georgia

Jonathan L. Kaufman, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

October
14
Friday
6:30 PM EDT

EOSINOPHILIC ESOPHAGITIS

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Sandeep K. Gupta, MD
Community Health Network
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana

October
17
Monday
6:45 AM CDT

ASTHMA

Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma

Leonard B. Bacharier, MD
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, Tennessee

Monica Kraft, MD
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York

October
23
Sunday
6:30 PM CDT

SOLID TUMORS

Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

November
5
Saturday
6:30 AM CDT
November
5
Saturday
12:00 PM EDT

HCC/LIVER CANCER

It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics

Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas

November
5
Saturday
6:00 PM CDT

HEART FAILURE

How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

Javed Butler, MD, MPH, MBA
Baylor Scott and White Research Institute
Dallas, Texas
University of Mississippi
Jackson, Mississippi

November
12
Saturday
8:30 PM EST

SEVERE ASTHMA

Leveling the Playing Field for All Patients With Severe Asthma: Directing New Treatment Approaches at the Airway Epithelium

Juan Carlos Cardet, MD
University of South Florida
Tampa, Florida

Geoffrey L. Chupp, MD
Yale School of Medicine
Yale Center for Asthma and Airway Disease
Yale New Haven Hospital
New Haven, Connecticut

November
16
Wednesday
12:45 CET

BREAST CANCER

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

Professor Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
Bart's Cancer Institute, Queen Mary University of London
London, England, United Kingdom

November
17
Thursday
5:30 PM EST

GLIOBLASTOMA

Setting Our Sights on Improved Outcomes in Glioblastoma Multiforme: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

December
9
Friday
7:30 AM CST

LYMPHOMA

The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care

Jason Westin, MD, MS, FACP
The University of Texas
MD Anderson Cancer Center
Houston, Texas

December
9
Friday
7:30 AM CST

COLD AGGLUTININ DISEASE (CAD)

Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs

Sigbjørn Berentsen, MD, PhD
Haugesund Hospital
Haugesund, Norway

Ilene C. Weitz, MD
Keck-USC School of Medicine
Los Angeles, California

December
9
Friday
7:30 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
9
Friday
7:30 AM CST

DIFFUSE LARGE B-CELL LYMPHOMA

Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
9
Friday
7:30 AM CST

MULTIPLE MYELOMA

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts

December
9
Friday
7:30 AM CST

LEUKEMIA

The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care

Jerald Radich, MD
Fred Hutchinson Cancer Center
Seattle, Washington

December
9
Friday
7:30 AM CST

LYMPHOMA

Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

December
9
Friday
7:30 AM CST

ACUTE MYELOID LEUKEMIA

Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

December
9
Friday
11:00 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
10
Friday
7:30 AM EST

CAR-T Therapy

Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

December
10
Friday
11:30 AM EST

Chronic Lymphocytic Leukemia

Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

Live event schedule coming soon. Questions about upcoming live events can be sent to live@PeerView.com.
September
10
Friday
7:15 PM MDT

Hypertrophic Cardiomyopathy

Easing the Burden of Hypertrophic Cardiomyopathy: Progress in Understanding and Addressing Its Pathophysiology

Aurora, Colorado

Daniel Jacoby, MD
Yale New Haven Health
Yale School of Medicine
New Haven, Connecticut

October
22
Friday
5:30 PM PDT

Eosinophilic Esophagitis

Fulfilling a Need in the Management of Patients With Eosinophilic Esophagitis: An Exploration of Novel and Emerging Therapeutic Options

Las Vegas, NV

Evan S. Dellon, MD, MPH
UNC Center for Esophageal Diseases and Swallowing (CEDAS)
University of North Carolina School of Medicine
Chapel Hill, North Carolina

October
24
Sunday
6:00 PM CDT

Pan Tumor

Implementing Synergistic Multimodal Approaches With Tumor Treating Fields to Extend Survival in Aggressive Cancers

Chicago, IL

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

October
25
Monday
6:30 AM EDT

Immune-Related Adverse Events

Maintaining Vigilance to Mitigate Cancer Immunotherapy-Related Toxicities in the Emergency Department: Be Aware, Stay Alert, and Change Your Practice

Boston, MA

Mark M. Awad, MD, PhD
Lowe Center for Thoracic Oncology
Harvard Medical School
Boston, Massachusetts

October
26
Tuesday
6:30 AM EDT

Multiple Sclerosis

Exploring the Convergence of Advances in S1P Receptor Modulation With Progress in Understanding Brain Atrophy and Cognition Measures in Multiple Sclerosis

Orlando, Florida

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

October
27
Wednesday
6:30 PM EDT

Multiple Sclerosis

Bruton Tyrosine Kinase Inhibitors for MS: Progress in the Development of an Emerging Therapeutic Approach

Orlando, Florida

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

October
29
Friday
12:15 PM EDT

NSCLC

Time for Even More Precision in Testing and Treatment of EGFR-Mutated NSCLC: Refining and Expanding Best Practices in Advanced and Early-Stage Disease Settings

Boston, MA

Lynette M. Sholl, MD
Brigham and Women’s Hospital
Harvard Medical School
Boston, Massachusetts

November
4
Thursday
8:30 PM EDT

Renal Cell Carcinoma

Selecting and Sequencing Targeted and Immunotherapy Regimens for RCC: How Will the Latest Evidence Impact Treatment Decisions for My Patients?

Austin, TX

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

November
20
Saturday
12:15 PM EST

Glioblastoma

A New Wave of Progress in Glioblastoma: Expert Guidance on Delivering Modern Personalized Care With Tumor Treating Fields and Novel Systemic Approaches

Boston, MA

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Tuesday
5:30 PM EST

Bladder Cancer

Breaking Down the Evidence in Bladder Cancer: Expert Perspectives and Practical Strategies on Immune, Targeted, and Antibody-Based Therapies

Orlando, FL

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

December
1
Wednesday
6:30 AM EST

Prostate Cancer

Personalizing and Advancing Modern Treatment Approaches to Prostate Cancer

Orlando, FL

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

Pedro C. Barata, MD, MSc
Tulane University Medical School
New Orleans, Louisiana

December
10
Friday
7:00 AM EST

Chronic Lymphocytic Leukemia

Customizing Care in CLL With BTK Inhibitors: Evidence and Applications for Therapy Selection, Sequencing, and Safety Management

Atlanta, GA

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
10
Friday
7:00 AM EST

Diffuse Large B-Cell Lymphoma

Taking the Turn to Treatment Innovation in DLBCL: Real-World Insight on Integrating Antibodies and Cellular Therapy Into Patient Care

Atlanta, GA

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
10
Friday
7:00 AM EST

CAR-T Therapy

Unlocking the Benefits of CAR-T Therapy in Hematologic Malignancies: Latest Evidence and Practical Considerations for Delivering State-of-the-Art Care

Atlanta, GA

Caron Jacobson, MD
Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

December
10
Friday
7:00 AM EST

Acute Myeloid Leukemia

Seizing Opportunity in AML: How to Realize the Potential of Novel Therapeutics in Diverse Patient Populations

Atlanta, GA

Naval Daver, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

December
10
Friday
7:00 AM EST

Multiple Myeloma

A Is for Antibody in Multiple Myeloma: Practical Insights and Patient Voices Along the Therapeutic Journey

Atlanta, GA

Suzanne Lentzsch, MD, PhD
Columbia University Medical Center
New York, New York

December
10
Friday
7:00 AM EST

Sickle Cell Disease

The Evolution of Sickle Cell Disease: Current Advances and Future Possibilities

Atlanta, GA

Biree Andemariam, MD
University of Connecticut Health
Farmington, Connecticut

December
10
Friday
11:00 AM EST

Chronic Lymphocytic Leukemia

Achieving Innovation in CLL Care: Evidence-Informed Choices With Targeted Options and Next Steps in Disease Management

Atlanta, GA

John G. Gribben, MD, DSc, FRCP, FRCPath, FMedSci
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

January
20
Thursday
6:00 PM PST

Hepatocellular Carcinoma

Mapping the Optimal Treatment Route in HCC: Identifying Best Practices in an Expanding Therapeutic Landscape

San Francisco, CA

Richard S. Finn, MD
David Geffen School of Medicine at UCLA
Los Angeles, California

January
21
Friday
6:00 PM PST

Biliary Cancers

Embracing the Era of Individualized Therapy in Advanced Biliary Cancers: Expert Strategies for Applying New and Emerging Targeted Treatment Options Through Precision Medicine

San Francisco, CA

Milind Javle, MD
The University of Texas MD Anderson Cancer Center
Houston, Texas

February
9
Wednesday
6:30 PM CST

Stroke

Mastering the Use of Dual Antiplatelet Therapy for Preventing Recurrent Stroke: How Well Do Your Current Strategies Match With the Experts?

New Orleans, LA

Gregory W. Albers, MD
Stanford University
Stanford Stroke Center
Stanford, California

S. Claiborne “Clay” Johnston, MD, PhD
Dell Medical School
The University of Texas at Austin
Austin, Texas

February
17
Thursday
6:45 PM PST

Renal Cell Carcinoma

Navigating Evolving Standards of Care in Renal Cell Carcinoma: Expert Insights on Selecting and Sequencing Targeted and Immunotherapy Options and a Look at Emerging Strategies

San Francisco, CA

Sumanta Kumar Pal, MD, FASCO
City of Hope Comprehensive Cancer Center
Duarte, California

February
17
Thursday
6:45 PM PST

Bladder Cancer

Achieving State-of-the-Art Care in Bladder Cancer in an Era of Innovative Therapeutic Solutions

San Francisco, CA

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

February
18
Friday
6:15 PM PST

Prostate Cancer

Decisions and Dilemmas in Prostate Cancer Management: Building on Progress to Advance Personalized Care Through Candid Conversations and Expert Clinical Consults

San Francisco, CA

Robert Dreicer, MD, MS, MACP, FASCO
University of Virginia Comprehensive Cancer Center
Paul Mellon Urologic Cancer Institute
University of Virginia School of Medicine
Charlottesville, Virginia

February
25
Friday
6:30 PM EST

Multiple Sclerosis

Rationale, Evidence, and Practical Potential for BTK Inhibitors in Patient-Centered MS Care: Where We Stand Now

West Palm Beach, FL

Amit Bar-Or, MD, FRCPC
Center for Neuroinflammation and Experimental Therapeutics
Perelman Center for Advanced Medicine (PCAM)
University of Pennsylvania
Philadelphia, Pennsylvania

Daniel S. Reich, MD, PhD
National Institute of Neurological Disorders and Stroke
National Institutes of Health*
Bethesda, Maryland

*Participation in this CME event as an "outside activity"

February
28
Monday
6:30 AM MST

Severe Asthma

Taking It From the Top: Targeting a New Approach to Controlling Severe Asthma

Phoenix, AZ

Purvi S. Parikh, MD, FACP, FACAAI
New York University School of Medicine
New York, New York

Cedric "Jamie" Rutland, MD
American Lung Association
Rutland Medical Group
UCR School of Medicine
Newport Beach, California

March
10
Thursday
6:45 PM CST

Melanoma

Linking Immunotherapy to Better Outcomes in Resectable Melanoma: Guidance on Integrating Immune-Based Adjuvant and Neoadjuvant Options

Dallas, TX

Jennifer Wargo, MD, MMSc
The University of Texas MD Anderson Cancer Center
Houston, Texas

March
11
Friday
4:45 PM CST

Breast Cancer

Translating Progress With Immunotherapies and Targeted Agents Into Improved Outcomes in Triple-Negative Breast Cancer: Surgical and Clinical Perspectives on Modern Multimodal Treatment Approaches

Dallas, TX

Henry M. Kuerer, MD, PhD, FACS
The University of Texas MD Anderson Cancer Center
Houston, Texas

Heather L. McArthur, MD, MPH
UT Southwestern Medical Center
Dallas, Texas

March
17
Thursday
5:00 PM CET

Alzheimer’s Disease

Accelerating Progress in the Treatment of Alzheimer’s Disease: How Can We Achieve Timely and Accurate Neuropathological Diagnosis and Precision Management of Mild Cognitive Impairment in Early Alzheimer’s Disease?

Barcelona, Spain

Liana G. Apostolova, MS, MD, FAAN
Indiana University School of Medicine
Indiana Alzheimer's Disease Center
Indianapolis, Indiana

March
22
Tuesday
6:00 AM PDT

Immuno-Oncology Biomarkers

Progress and Practicalities in Immunotherapy Biomarker Testing and Pathologic Response Assessment in Solid Tumors: What’s New and What You Need to Know and Do

Los Angeles, CA

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
23
Wednesday
6:00 AM PDT

HER2/HER3/TROP2 Testing/Treatment

Decoding the Latest Evidence and Practical Recommendations on Biomarker Testing for New Therapeutic Options Targeting HER2, HER3, and TROP2 in Solid Tumors

Los Angeles, CA

Kurt A. Schalper, MD, PhD
Yale School of Medicine
Yale Cancer Center
New Haven, Connecticut

March
26
Saturday
6:30 PM EDT

Prurigo Nodularis

Addressing the Burden of Prurigo Nodularis: Expert Insight on Disease Pathogenesis and the Clinical Potential of Novel Therapeutic Options

Boston, MA

Sarina Elmariah, MD, PhD, MPH
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Shawn Kwatra, MD
Johns Hopkins University School of Medicine
Baltimore, Maryland

March
27
Sunday
6:30 PM EDT

Chronic Spontaneous Urticaria

Advances in Chronic Spontaneous Urticaria: Expert Insight on Translating Progress to Practice for Improved Symptom Control and Quality of Life

Boston, MA

Joseph Diaz, MD
Allergy, Asthma, & Immunology Associates of South Texas
San Antonio, Texas

Erika Gonzalez, MD
South Texas Allergy & Asthma Medical Professionals
University of Texas Health Science Center
San Antonio, Texas

April
9
Saturday
6:30 PM CDT

Cancer Immunotherapy

Parsing the Practicalities of Pathologic Response Assessment After Neoadjuvant Immunotherapy to Facilitate Progress in Early-Stage Cancers

New Orleans

Prof. Solange Peters, MD, PhD
University Hospital of Lausanne
Lausanne, Switzerland

April
24
Sunday
12:00 PM MST

Graft-Versus-Host Disease

Overcoming the Challenges of Acute and Chronic GVHD: The Integration of Novel Therapies Into Modern Management Protocols

Salt Lake City, UT

Leslie Kean, MD, PhD
Harvard Medical School
Boston Children's Hospital
Dana-Farber Cancer Institute
Boston, Massachusetts

April
25
Monday
6:30 AM MDT

Acute Myeloid Leukemia

Landmarks Across the Patient Journey in AML: Applying Evidence With Novel Therapeutics Pre- and Post-AlloHCT

Salt Lake City, UT

James M. Foran, MD, FRCPC
Mayo Clinic Cancer Center
Jacksonville, Florida

April
25
Monday
7:00 AM MDT

Leukemia

CAR-T Cell Therapy: Are You Up to the Challenge? New Evidence and Best Practices Driving Modern Cellular Therapies as a Standard of Care for Leukemia and Lymphoma

Salt Lake City, UT

Michael R. Bishop, MD
The David and Etta Jonas Center for Cellular Therapy
University of Chicago
Chicago, Illinois

April
26
Tuesday
6:30 AM MDT

Myelofibrosis

The Modern Management of Myelofibrosis: Practical Perspectives Surrounding the Use of JAK Inhibitors and Novel Therapeutics in the Peri-Transplant Setting

Salt Lake City, UT

Jeanne M. Palmer, MD
Mayo Clinic
Phoenix, Arizona

Srdan Verstovsek, MD, PhD
The University of Texas MD Anderson Cancer Center
Houston, Texas

April
26
Tuesday
6:30 AM MST

Chronic Lymphocytic Leukemia

Reaping the Rewards of Innovative Care in CLL: From Targeted Standards to Cellular Therapy

Salt Lake City, UT

John N. Allan, MD
Weill Cornell Medicine
New York, New York

Alexey V. Danilov, MD, PhD
Toni Stephenson Lymphoma Center
City of Hope National Medical Center
Duarte, California

April
26
Tuesday
11:30 AM MDT

Veno-Occlusive Disease

Upgrading the VOD/SOS Management Tool Kit: Guidance for Effective Diagnostic Confirmation, Grading, and Treatment

Salt Lake City, UT

Nelson Chao, MD, MBA
Duke Cancer Institute/Duke Global Health Institute
Durham, North Carolina

Christine N. Duncan, MD
Dana-Farber/Boston Children's Cancer and Blood Disorders Center
Boston Children’s Hospital
Harvard Medical School
Boston, Massachusetts

April
28
Thursday
11:45 AM PDT

Solid Tumors

Tackling the Practicalities of Antibody–Drug Conjugate Therapy for Solid Tumors: Improving Clinical Care With HER2-, HER3-, and TROP2-Targeted Therapies

Anaheim, CA

Linda Ahn, MSN, ANP-BC, AOCNP
Memorial Sloan Kettering Cancer Center
New York, New York

April
29
Friday
5:30 AM PDT

Chronic Lymphocytic Leukemia

Hope Is Here in CLL: Oncology Nurse Strategies for Delivering Effective, Compassionate, and Modern Care to Patients

Anaheim, CA

Amy Goodrich, CRNP
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland

April
30
Saturday
5:30 PM PDT

Renal Cell Carcinoma

Aligning Nursing Care Strategies With Evolving Patient Needs in RCC: Interprofessional Insights on Optimizing Outcomes With Novel Targeted and Immune-Based Therapies

Anaheim, CA

Nancy P. Moldawer, RN, MSN
Cedars-Sinai Medical Center
Los Angeles, California

May
5
Thursday
7:00 AM EDT

Neurofibromatosis

Revolutionizing the Standard of NF1 Care: Insights on Innovative MEK-Inhibitor Options for NF1-Associated PNs

Pittsburgh, PA

Bruce R. Korf, MD, PhD
UAB School of Medicine
University of Alabama at Birmingham
Birmingham, Alabama

Miriam Bornhorst, MD
Children’s National Hospital
Washington, DC

May
5
Thursday
12:15 PM EDT

Acute Lymphoblastic Leukemia

Adapting to Innovation in Pediatric ALL: Guidance on Optimizing Modern Therapy and the Role of Novel Asparaginase Compounds

Pittsburgh, PA

Stuart S. Winter, MD
Children's Minnesota
Minneapolis, Minnesota

Reuven Schore, MD
Children’s National Hospital
The George Washington University School of Medicine and Health Sciences
Washington, District of Columbia

May
14
Saturday
5:30 PM CDT
May
14
Saturday
12:00 PM EDT

NSCLC

How to Integrate Perioperative Immunotherapy Into Multimodal Treatment Plans to Improve Outcomes in Resectable NSCLC

Boston, MA

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

June
2
Thursday
6:30 AM EDT

Multiple Sclerosis

Innovations and Imaging in Multiple Sclerosis: Examining the Evidence, Looking Toward the Future of Bruton Tyrosine Kinase Inhibitors

National Harbor, MD

Benjamin M. Greenberg, MD, MHS
University of Texas Southwestern Medical Center
Dallas, Texas

Professor Anthony Traboulsee, MD
The MS Society
The University of British Columbia
Vancouver, British Columbia, Canada

June
3
Friday
6:30 PM CDT

Chronic Lymphocytic Leukemia

Rewriting the Treatment Script in CLL: Guidance on Integrating Modern Targeted and Next-Gen Options Into Patient Care

Chicago, Illinois

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
3
Friday
6:30 AM EDT

Multiple Sclerosis

Re-Examining S1PR Modulation From All Angles in Relapsing Multiple Sclerosis: Impact on Physical and Cognitive Outcomes, and Practical Considerations of Long-Term Therapy

National Harbor, MD

Bruce Cree, MD, PhD, MAS
UCSF Weill Institute for Neurosciences
University of California San Francisco
San Francisco, California

June
3
Friday
6:30 PM CDT

Melanoma

New Rules for Sequential Care in BRAF-Mutated Melanoma: Rethinking Upfront Selection and Sequencing of Immunotherapy and Targeted Agents in Metastatic Disease

Chicago, Illinois

Hussein A. Tawbi, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

June
3
Friday
6:30 PM CDT

AML

The Advantage of Innovation in AML: Guidance on Developing and Delivering Effective and Highly Personalized Care

Chicago, IL

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

June
3
Friday
6:30 PM CDT

Small Cell Lung Cancer

Assessing the Impact of Therapeutic Advances in SCLC: Instilling New Hope and Moving in Leaps and Bounds Toward Better Outcomes

Chicago, IL

Jacob Sands, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
3
Friday
6:30 PM CDT

RCC

Refining RCC Management Across the Disease Continuum: An Expert Clinical Consult on Leveraging New Evidence and Novel Therapeutic Strategies to Personalize Patient Care

Chicago, IL

Toni K. Choueiri, MD
Lank Center for Genitourinary Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
5:30 AM CDT

DR/DME

A Call to Action for Diabetes Specialists: Your Role in Saving the Eyesight of Patients With Diabetes

New Orleans, Louisiana

Richard Beaser, MD
Joslin Diabetes Center
Harvard Medical School
Boston, Massachusetts

June
4
Saturday
12:30 PM EDT

COVID-19

Do You Know How to Use COVID-19 Monoclonal Antibodies as Pre-Exposure Prophylaxis for Your Post-Transplant Patients? Test Your Knowledge

Boston, MA

Shmuel Shoham, MD
Professor of Medicine
Transplant and Oncology Infectious Diseases Program
Division of Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, Maryland

Myron S. Cohen, MD
Yeargan-Bate Eminent Professor of Medicine, Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director, Institute for Global Health and Infectious Diseases
University of North Carolina at Chapel Hill
Chapel Hill, North Carolina

June
4
Saturday
6:30 PM CDT

CAR-T THERAPY

Rising to the Occasion: Improving Outcomes in Leukemia, Lymphoma, and Multiple Myeloma With CAR-T Therapy in Community Practice

Chicago, IL

Jason Westin, MD, MS, FACP
The University of Texas MD Anderson Cancer Center
Houston, Texas

June
4
Saturday
6:30 PM CDT

HCC/LIVER CANCER

Setting the Course for the Optimal Management of HCC: Improving Patient Outcomes Through the Integration of Novel Therapeutic Approaches Across the Continuum of Care

Chicago, IL

Richard S. Finn, MD
Professor of Clinical Medicine
Division of Hematology/Oncology
David Geffen School of Medicine at UCLA
Los Angeles, California

June
4
Saturday
6:30 PM CDT

NSCLC

Find the Targets, Treat With Precision: Modern Principles and New Advances in Biomarker-Driven Lung Cancer Care

Chicago, IL

Stephen V. Liu, MD
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

June
4
Saturday
6:30 PM CDT

MULTIPLE MYELOMA

The “Myelennial” Generation: Managing the Boom of Innovative Therapy to Transform Myeloma Care and Enhance Patient Outcomes

Chicago, IL

Nina Shah, MD
UCSF Helen Diller Family Comprehensive Cancer Center
The University of California, San Francisco
San Francisco, California

June
4
Saturday
6:30 PM CDT

HEAD AND NECK CANCER

The Power and Promise of Immunotherapy in Head and Neck Cancer: How Established and Emerging Immune-Based Options Can Enhance Patient Care

Chicago, IL

Robert I. Haddad, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

June
5
Sunday
6:30 PM CDT

NSCLC

Gaining an Advantage Over NSCLC: How to Achieve the Greatest Benefit With Immunotherapy From Advanced to Early Disease

Chicago, IL

David P. Carbone, MD, PhD
International Association for the Study of Lung Cancer
James Thoracic Oncology Center
James Cancer Center
The Ohio State University Medical Center
Columbus, Ohio

June
5
Sunday
6:30 PM CDT

MELANOMA

Choosing Innovation With Immunotherapy in Melanoma: Guidance on Utilizing Immune-Based and Other Novel Options in Resectable and Unresectable Disease

Chicago, IL

Michael B. Atkins, MD
Georgetown-Lombardi Comprehensive Cancer Center
Georgetown University School of Medicine
Washington, District of Columbia

June
5
Sunday
6:30 PM CDT

BASAL CELL CARCINOMA

Immunotherapy Has Arrived in Advanced BCC: Collaborative Strategies for Making the Most of Novel Immune-Based Treatment

Chicago, IL

Karl D. Lewis, MD
University of Colorado Anschutz Medical Campus
University of Colorado Cancer Center
Aurora, Colorado

June
5
Sunday
6:30 PM CDT

BLADDER CANCER

Blazing the Trail Forward in the Therapeutic Management of Bladder Cancer: Expert Insights on Incorporating the Latest Evidence and Treatment Advancements Into Practice Across the Disease Continuum

Chicago, IL

Petros Grivas, MD, PhD
University of Washington
Fred Hutchinson Cancer Research Center
Seattle, Washington

June
5
Sunday
6:30 PM CDT

METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER

Realizing the Potential of Novel Treatment Intensification Strategies for Metastatic Castration-Sensitive Prostate Cancer: The Experts’ Take on Key Clinical Evidence, Practical Considerations, and Best Practices for Individualized, Patient-Centered Care

Chicago, IL

Matthew R. Smith, MD, PhD
Harvard Medical School
Massachusetts General Hospital Cancer Center
Boston, Massachusetts

June
9
Thursday
07:45 CEST

B-Cell Cancers

Upgrading the Sequential Therapy Tool Kit for B-Cell Malignancies: New Evidence on the Individualized Use of BTK Inhibitors in Relapsed/Refractory CLL/SLL and MCL

Wien, Austria

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

Anthony R. Mato, MD, MSCE
Memorial Sloan Kettering Cancer Center
New York, New York

June
9
Thursday
10:00 CEST

Chronic Lymphocytic Leukemia

New Rules for BTK Inhibitors in CLL: Benchmarks for Evidence-Based Treatment Selection, Sequencing, and Safety Management

Wien, Austria

Prof. Dr. med. Stephan Stilgenbauer
Comprehensive Cancer Center Ulm
Ulm University
Ulm, Germany

June
10
Friday
17:45 CEST

ACUTE LYMPHOBLASTIC LEUKEMIA

The Path for Better Outcomes in ALL: Integrating Modern Asparaginase Compounds Into the Care of Pediatric, AYA, and Adult Patients

Wien, Austria

Prof. Carmelo Rizzari
President of the European Society of Pediatric Oncology (SIOPE)
Professor of Pediatrics
University of Milano-Bicocca
Head, Pediatric Hematology Oncology Unit
MBBM Foundation, ASST Monza
Monza, Italy

June
15
Wednesday
11:45 AM EDT
July
1
Friday
13:25 CEST

Gastric Cancer

Realizing Improved Outcomes in HER2-Positive Gastrointestinal Cancers: New Evidence and Practical Guidance With Targeted Agents

Barcelona, Spain

Elena Elez, MD, PhD
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Yelena Y. Janjigian, MD
Memorial Sloan Kettering Cancer Center
New York, New York

July
23
Saturday
7:00 AM PDT

Prurigo Nodularis

Taking a New Look at Prurigo Nodularis: How Is Emerging Evidence Regarding Disease Pathophysiology and Treatment Influencing Patient Care?

Vancouver, BC

Sarah S. Chisolm, MD
Emory University
VISN 7, VA
Atlanta, Georgia

Brian S. Kim, MD, MTR
Friedman Brain Institute
Icahn School of Medicine at Mount Sinai
New York, New York

September
9
Friday
10:00 CEST

Breast Cancer

Targeting HER2-Low Expression in Breast Cancer: Evaluating the Evidence, Challenges, and Opportunities for Expanding Treatment Benefit to More Patients

Paris, France

Professor Aleix Prat, MD, PhD
Hospital Clínic Barcelona
University of Barcelona
Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)
Barcelona, Spain

September
9
Friday
18:00 CEST
September
24
Saturday
6:30 AM CDT

Small Cell Lung Cancer

Improving Outcomes in SCLC Through Optimal Integration of the Latest Therapies: Expert Perspectives on the State of the Science, Best Practices, Multidisciplinary Care, and Future Directions

Chicago, IL

Taofeek K. Owonikoko, MD, PhD
University of Pittsburgh
UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania

September
24
Saturday
7:00 PM CDT
September
25
Sunday
6:30 AM CDT

NSCLC

Refining Biomarker Testing and Targeted Treatment of NSCLC With Common and Uncommon EGFR Mutations

Chicago, IL

Natasha B. Leighl, MD, MMSc, FRCPC, FASCO
Princess Margaret Cancer Centre
PMC Foundation
University of Toronto
Dalla Lana School of Public Health
Toronto, Ontario, Canada

September
28
Wednesday
12:41 PM CDT

ACUTE MYELOID LEUKEMIA

The Power of Personalized Medicine in AML: Linking Individualized Treatment to Enhanced Patient Outcomes

Houston, TX

Naval Daver, MD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Amir T. Fathi, MD
Massachusetts General Hospital Cancer Center
Harvard Medical School
Boston, Massachusetts

September
28
Wednesday
12:41 PM CDT

CHRONIC LYMPHOCYTIC LEUKEMIA

Challenges and Changes With Targeted Options in CLL: Guidance on Making Evidence-Informed Upfront and Sequential Treatment Choices

Houston, TX

Nicole Lamanna, MD
Herbert Irving Comprehensive Cancer Center
New York-Presbyterian/Columbia University Medical Center
New York, New York

Deborah M. Stephens, DO
University of Utah/Huntsman Cancer Institute
Salt Lake City, Utah

September
29
Thursday
11:50 AM CDT

MULTIPLE MYELOMA

Progress on the Path to Better Outcomes in RRMM: Expert Perspectives on the Further Integration of BCMA-Directed Antibodies and Cellular Therapies

Houston, TX

Sagar Lonial, MD, FACP
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Krina Patel, MD, MSc
The University of Texas
MD Anderson Cancer Center
Houston, Texas

September
30
Friday
12:15 PM EDT

NSCLC

Precision Decisions in Multimodal Management of Early-Stage NSCLC: Integrating EGFR-Targeted Therapy in Perioperative Settings

New York, NY

Brendon M. Stiles, MD
Montefiore-Einstein Cancer Center
Albert Einstein College of Medicine
Montefiore Medical Center
New York, New York

September
30
Friday
6:30 PM EDT

NSCLC

Extending Survival and Setting Our Sights on Cure in Resectable NSCLC: Getting the Details of Perioperative Immunotherapy Right

New York, NY

Nasser Altorki, MD
Weill Cornell Medicine
Meyer Cancer Center of Weill Cornell
New York, New York

Jonathan D. Spicer, MD, PhD, FRCSC
McGill University
Montreal General Hospital
Montreal, Quebec, Canada

September
30
Friday
6:30 PM CDT

MULTIPLE MYELOMA

The Eye-Deal Connection in Multiple Myeloma: Establishing Ophthalmology-Oncology Relationships to Overcome Ocular Toxicity

Chicago, IL

Praneetha Thulasi, MD
Emory Eye Center
Emory University School of Medicine
Atlanta, Georgia

Jonathan L. Kaufman, MD
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

October
1
Saturday
5:30 PM EDT

GENERALIZED MYASTHENIA GRAVIS

A Targeted Approach to Management of Generalized Myasthenia Gravis: The Latest on Novel Therapies That Improve Patient Outcomes

National Harbor, MD

James F. Howard Jr., MD
The University of North Carolina
Chapel Hill, North Carolina

October
2
Sunday
6:30 AM EDT

Hypertrophic Cardiomyopathy

Pushing Back Against HCM: Can Cardiac Myosin Inhibitors Alter the Disease Progression and Management Trajectory for Patients With Hypertrophic Cardiomyopathy?

National Harbor, MD

Milind Desai, MD, MBA
Cleveland Clinic Lerner College of Medicine
HCM Center
Heart and Vascular Institute
Cleveland, Ohio

October
14
Friday
6:00 PM EDT

EOSINOPHILIC ESOPHAGITIS

Updates in Eosinophilic Esophagitis: Exploring Underlying Mechanisms and Integrating Novel Targeted Therapy to Improve Patient Care

Orlando, FL

Sandeep K. Gupta, MD
Community Health Network
Riley Hospital for Children
Indiana University School of Medicine
Indianapolis, Indiana

October
17
Monday
6:15 AM CDT

ASTHMA

Selecting Targeted Treatment for Pediatric and Adult Patients With Uncontrolled Moderate to Severe Asthma

Nashville, TN

Leonard B. Bacharier, MD
Monroe Carell Jr. Children’s Hospital at Vanderbilt University Medical Center
Nashville, Tennessee

Monica Kraft, MD
Icahn School of Medicine at Mount Sinai
Mount Sinai Health System
New York, New York

October
23
Sunday
6:00 PM CDT

SOLID TUMORS

Harnessing Novel Synergies With Tumor Treating Fields: Insights on Improving Survival With Multimodal Care in Aggressive Tumors

San Antonio, TX

Erik P. Sulman, MD, PhD
NYU Grossman School of Medicine
Laura and Isaac Perlmutter Cancer Center
New York, New York

November
5
Saturday
6:00 AM CDT
November
5
Saturday
11:30 AM EDT

HCC/LIVER CANCER

It Takes a Team for HCC: Improving Outcomes Through Multidisciplinary Collaboration & Modern Therapeutics

Washington, DC

Amit Singal, MD, MS
UT Southwestern Medical Center
Dallas, Texas

November
5
Saturday
5:30 PM CDT

HEART FAILURE

How I Think, How I Treat: Cardiology-Focused Perspectives on Using SGLT2 Inhibitors to Optimize Outcomes in Patients With Heart Failure

Chicago, IL

Javed Butler, MD, MPH, MBA
Baylor Scott and White Research Institute
Dallas, Texas
University of Mississippi
Jackson, Mississippi

November
12
Saturday
8:00 PM EST

SEVERE ASTHMA

Leveling the Playing Field for All Patients With Severe Asthma: Directing New Treatment Approaches at the Airway Epithelium

Louisville, KY

Juan Carlos Cardet, MD
University of South Florida
Tampa, Florida

Geoffrey L. Chupp, MD
Yale School of Medicine
Yale Center for Asthma and Airway Disease
Yale New Haven Hospital
New Haven, Connecticut

November
15
Tuesday
7:30 AM EST

LUPUS

How I Think, How I Treat—Assessing, Managing, and Engaging Patients to Optimize Care in SLE and LN: Comparing Approaches With the Experts

Philadelphia, PA

Maureen A. McMahon, MD
UCLA David Geffen School of Medicine
Los Angeles, California

November
16
Wednesday
12:15 CET

BREAST CANCER

TROP2-Targeting ADCs as New Tools in the TNBC and HR+/HER2- Breast Cancer Treatment Arsenal: Advancing Patient-Centered Care to Make the Most of Modern Targeted Treatments

Barcelona, Spain

Professor Peter Schmid, FRCP, MD, PhD
Centre for Experimental Cancer Medicine
Bart's Cancer Institute, Queen Mary University of London
London, England, United Kingdom

November
17
Thursday
5:15 PM EST

GLIOBLASTOMA

Setting Our Sights on Improved Outcomes in Glioblastoma Multiforme: State-of-the-Art Care With Tumor Treating Fields and Other Innovative Approaches

Tampa, FL

Steven Brem, MD
Penn Brain Tumor Center
Perelman School of Medicine
Abramson Cancer Center, University of Pennsylvania
Philadelphia, Pennsylvania

November
30
Wednesday
6:30 AM PST
December
9
Friday
7:00 AM CST

LYMPHOMA

The Rising Tide of CAR-T in Lymphoma: Guidance on Leveraging Cellular Therapy to Improve Outcomes Across the Spectrum of Care

New Orleans, LA

Jason Westin, MD, MS, FACP
The University of Texas
MD Anderson Cancer Center
Houston, Texas

December
9
Friday
7:00 AM CST

COLD AGGLUTININ DISEASE (CAD)

Demystifying Cold Agglutinin Disease: A Visual Exploration of Mechanism, Diagnosis, and the Role of Complement Inhibition in Addressing Unmet Needs

New Orleans, LA

Sigbjørn Berentsen, MD, PhD
Haugesund Hospital
Haugesund, Norway

Ilene C. Weitz, MD
Keck-USC School of Medicine
Los Angeles, California

December
9
Friday
7:00 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

The Winning Way With BTK Inhibitors in CLL: Evidence-Informed Choices on Treatment Selection, Safety, and Therapeutic Sequencing

New Orleans, LA

John C. Byrd, MD
University of Cincinnati College of Medicine
Cincinnati, Ohio

December
9
Friday
7:00 AM CST

DIFFUSE LARGE B-CELL LYMPHOMA

Real-World, Real Innovation in DLBCL: Perspectives on Integrating Novel Antibody Platforms Into Patient Care

New Orleans, LA

Grzegorz (Greg) Nowakowski, MD
Mayo Clinic
Rochester, Minnesota

December
9
Friday
7:00 AM CST

MULTIPLE MYELOMA

The Road to Remission in Multiple Myeloma: Expert Guidance on Using BCMA-Targeted Options to Enhance Clinical Outcomes

New Orleans, LA

Nikhil C. Munshi, MD
Jerome Lipper Multiple Myeloma Center
Harvard Medical School
Boston, Massachusetts

December
9
Friday
7:00 AM CST

LEUKEMIA

The Sequel to the Targeted Therapy Era in CML: Guidance on Integrating Novel Options Into Cohesive Sequential Care

New Orleans, LA

Jerald Radich, MD
Fred Hutchinson Cancer Center
Seattle, Washington

December
9
Friday
7:00 AM CST

LYMPHOMA

Fixing the Target on Aggressive Lymphoma: Guidance on the Next Phase of Integrating Targeted Agents Into MCL and DLBCL Management

New Orleans, LA

Dr. Toby A. Eyre, MBChB, DipMedEd, MRCP, FRCPath, MD
Oxford University Hospitals
NHS Foundation Trust
Oxford, United Kingdom

December
9
Friday
7:00 AM CST

ACUTE MYELOID LEUKEMIA

Maintaining “Intensity” for Better Outcomes in AML: Guidance on Modern, Intensive Upfront Platforms in Challenging Patient Populations

New Orleans, LA

Gail J. Roboz, MD
Weill Cornell Medical College
New York Presbyterian Hospital
New York, New York

December
9
Friday
11:00 AM CST

CHRONIC LYMPHOCYTIC LEUKEMIA

Fine-Tuning the Wave of Innovation in CLL: Personalized Models for Upfront and Sequential Care With Groundbreaking Treatment

New Orleans, LA

Prof. John G. Gribben, MD, DSc
Barts Cancer Institute
Barts and The London School of Medicine, Queen Mary, University of London
London, England, United Kingdom

December
9
Friday
3:00 PM CST